Baylor University Medical Center
Cardiovascular Disease fellowship · Dallas, TX · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Baylor University Medical Center's research in cardiovascular disease, which the program shares with other departments and affiliated hospitals.
About Baylor University Medical Centerinstitution-wide cardiovascular disease research
Cardiovascular Disease publications from Baylor University Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
77
works per year
40th of 78 cardiovascular disease fellowship programs
-33.2%
2-year growth
78th of 78 cardiovascular disease fellowship programs
42.4%
in top 10% of field (works before 2025)
1st of 74 cardiovascular disease fellowship programs
54.1%
cited above world average
9th of 74 cardiovascular disease fellowship programs
Works per year · * 2026 so far
Cardiology and Cardiovascular Medicine · 350
Cardiovascular Disease research topics at Baylor University Medical Center
Papers in the window; each links to the list on OpenAlex.
- Heart Failure Treatment and Management 194
- Cardiac Valve Diseases and Treatments 54
- Atrial Fibrillation Management and Outcomes 14
- Acute Myocardial Infarction Research 13
- Cardiac pacing and defibrillation studies 13
- Cardiac Arrhythmias and Treatments 11
- Mechanical Circulatory Support Devices 6
- Cardiomyopathy and Myosin Studies 6
Most cited at Baylor University Medical Center since 2024
All cardiovascular disease papers there on OpenAlex
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityMilton Packer et al. · New England Journal of Medicine · 2024 · PubMed · cited 1,058
- Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart FailureChristopher M. Kramer et al. · Journal of the American College of Cardiology · 2024 · PubMed · cited 197
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection FractionMilton Packer · Journal of the American College of Cardiology · 2025 · PubMed · cited 190
- Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trialBarry A. Borlaug et al. · Nature Medicine · 2024 · PubMed · cited 161
- Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trialAlexander Peikert et al. · European Heart Journal · 2025 · PubMed · cited 120
- Incident heart failure and recurrent coronary events following acute myocardial infarctionJaved Butler et al. · European Heart Journal · 2025 · PubMed · cited 86
- Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and ObesityMichael R. Zile et al. · Circulation · 2024 · PubMed · cited 78
- Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart FailureNavin Rajagopalan et al. · JACC Heart Failure · 2024 · PubMed · cited 65
- Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and ObesityMilton Packer et al. · Journal of the American College of Cardiology · 2025 · PubMed · cited 56
- Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEFBarry A. Borlaug et al. · Journal of the American College of Cardiology · 2025 · PubMed · cited 45